Efficacy and safety of apremilast in chronic cutaneous sarcoidosis

Arch Dermatol. 2012 Feb;148(2):262-4. doi: 10.1001/archdermatol.2011.301. Epub 2011 Oct 17.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Male
  • Phosphodiesterase 4 Inhibitors / therapeutic use*
  • Sarcoidosis / drug therapy*
  • Severity of Illness Index
  • Skin Diseases / drug therapy*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Phosphodiesterase 4 Inhibitors
  • Thalidomide
  • apremilast

Associated data

  • ClinicalTrials.gov/NCT00794274